Jean-Yves Douillard MD, PhD
Professor Emeritus, Medical Oncology, University of Nantes; Senior Advisor, Integrated Centers of Oncology (ICO), Nantes, FranceDr. Jean-Yves Douillard is a leading international expert in lung cancer and gastrointestinal oncology, and, over the course of a long career, he has held a number of leadership positions, including at the University of Nantes, where he was Professor in Medical Oncology, and at the Integrated Centers of Oncology (ICO) in Nantes, as Head of the Medical Oncology Department and later as Director of Clinical and Translational Research. He has also held senior ESMO positions, serving as Educational Committee Chair and as a member of the Executive Board.
Throughout his career, Dr. Douillard has led clinical trials in lung cancer and gastrointestinal tumors and has investigated targeted therapies, publishing his work in leading scientific journals. His clinical interests also include early drug development and translational research.
Currently, Dr. Doullard is serving as Senior Advisor in early clinical trial research at the Integrated Centers of Oncology.
Recent Contributions to PracticeUpdate:
- ECC 2015 Recap: Small Cell Lung Cancer Recommendations From Dr. Jean-Yves Douillard
- Adjuvant Erlotinib vs Placebo in Patients With Stage IB-IIIA NSCLC
- Postoperative Radiation Therapy Improves Survival in Incompletely Resected NSCLC
- Third-Generation EGFR TKIs Take On the T790M Mutation in NSCLC
- ASCO 2015 Recap: Nivolumab vs Docetaxel in Second-Line Therapy for NSCLC
- Dr. Jean-Yves Douillard's 2015 ASCO Abstract Recommendations—Lung Cancer
- Pembrolizumab Targets PD-1 in Non–Small Cell Lung Cancer: KEYNOTE-001
- Rociletinib in EGFR-Mutated NSCLC
- AZD9291 in EGFR Inhibitor–Resistant NSCLC
- Pembrolizumab for Non–Small Cell Lung Cancer